Trial Profile

A Randomized, Open-Label, Controlled, Multicenter Phase 3 Trial of SYS6002 Versus Chemotherapy of Physician's Choice in Recurrent or Metastatic Cervical Cancer After Platinum-containing Chemotherapy and Anti-PD-(L)1 Agent Therapy

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CRB 701 (Primary) ; Docetaxel; Gemcitabine; Pemetrexed; Topotecan
Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Sponsors Corbus Pharmaceuticals; CSPC Megalith Biopharmaceutical

18 Nov 2025 New trial record
17 Nov 2025 Status changed from planning to not yet recruiting.
18 Oct 2025 According to a Corbus Pharmaceuticals media release, the company expects to initiate registrational studies by mid-2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com